Amgen (AMGN) Launches Pavblu As Rival To Regeneron's (REGN) Eylea - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Regeneron Pharma (REGN) PT Lowered to $1,175 at Evercore ISI
October 24, 2024 6:07 AM EDTEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,175.00 (from $1,250.00) while maintaining a Outperform rating.
The analyst comments "Were adjusting our REGN PT to $1175 to reflect an earlier bEylea launch. Shares are down ~18% since... More
Regeneron Pharma (REGN) PT Lowered to $1,050 at Wells Fargo
October 23, 2024 6:40 AM EDTWells Fargo analyst Mohit Bansal lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,050.00 (from $1,200.00) while maintaining a Overweight rating.
The analyst comments "What's new? The Federal Circuit Court has lifted its earlier temporary stay on AMGN launching its Eylea biosimilar. The... More
Regeneron (REGN) Weakness Tied to Report Court Rejects Request for Injunction for Eylea Generic
October 22, 2024 12:45 PM EDTRegeneron (NASDAQ: REGN) Weakness Tied to Report Court Rejects Request for Injunction for Eylea Generic
Shares down 4.5%... More
